Giuseppe Carrà1,2, Cristina Crocamo2, Francesco Bartoli2, Matthias Angermeyer3, Traolach Brugha4, Mondher Toumi5, Paul Bebbington1. 1. Division of Psychiatry, University College London, 149 Tottenham Court Road, LondonW1T 7NF, UK. 2. Department of Medicine and Surgery, University of Milano Bicocca, Via Cadore 48, Monza20900, Italy. 3. Department of Psychiatry, University of Leipzig, Johannisallee 20, 04137 Leipzig, Germany. 4. Department of Health Sciences, University of Leicester, College of Medicine, Biological Sciences and Psychology, University of Leicester, Centre for Medicine, University Road, LeicesterLE1 7RH, UK. 5. Laboratoire de Santé Publique, Université de la Méditerranée, Marseille, France.
Abstract
BACKGROUND: The interaction between positive, negative and depressive symptoms experienced by people with schizophrenia is complex. We used longitudinal data to test the hypothesis that depressive symptoms mediate the links between positive and negative symptoms. METHODS: We analyzed data from the European Schizophrenia Cohort, randomly sampled from outpatient services in France, Germany and the UK (N = 1208). Initial measures were repeated after 6 and 12 months. Depressive symptoms were identified using the Calgary Depression Scale for Schizophrenia (CDSS), while positive and negative symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). Latent variable structural equation modelling was used to investigate the mediating role of depression assessed at 6 months in relation to the longitudinal association between positive symptoms at baseline and negative symptoms at 12 months. RESULTS: We found longitudinal associations between positive symptoms at baseline and negative symptoms at 12 months, as well as between both of these and CDSS levels at 6 months. However depression did not mediate the longitudinal association between PANSS scores; all the effect was direct. CONCLUSIONS: Our findings are incompatible with a mediating function for depression on the pathway from positive to negative symptoms, at least on this timescale. The role of depression in schizophrenic disorders remains a challenge for categorical and hierarchical diagnostic systems alike. Future research should analyze specific domains of both depressive and negative symptoms (e.g. motivational and hedonic impairments). The clinical management of negative symptoms using antidepressant treatments may need to be reconsidered.
BACKGROUND: The interaction between positive, negative and depressive symptoms experienced by people with schizophrenia is complex. We used longitudinal data to test the hypothesis that depressive symptoms mediate the links between positive and negative symptoms. METHODS: We analyzed data from the European Schizophrenia Cohort, randomly sampled from outpatient services in France, Germany and the UK (N = 1208). Initial measures were repeated after 6 and 12 months. Depressive symptoms were identified using the Calgary Depression Scale for Schizophrenia (CDSS), while positive and negative symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS). Latent variable structural equation modelling was used to investigate the mediating role of depression assessed at 6 months in relation to the longitudinal association between positive symptoms at baseline and negative symptoms at 12 months. RESULTS: We found longitudinal associations between positive symptoms at baseline and negative symptoms at 12 months, as well as between both of these and CDSS levels at 6 months. However depression did not mediate the longitudinal association between PANSS scores; all the effect was direct. CONCLUSIONS: Our findings are incompatible with a mediating function for depression on the pathway from positive to negative symptoms, at least on this timescale. The role of depression in schizophrenic disorders remains a challenge for categorical and hierarchical diagnostic systems alike. Future research should analyze specific domains of both depressive and negative symptoms (e.g. motivational and hedonic impairments). The clinical management of negative symptoms using antidepressant treatments may need to be reconsidered.
Authors: Paris Alexandros Lalousis; Stephen J Wood; Lianne Schmaal; Katharine Chisholm; Sian Lowri Griffiths; Renate L E P Reniers; Alessandro Bertolino; Stefan Borgwardt; Paolo Brambilla; Joseph Kambeitz; Rebekka Lencer; Christos Pantelis; Stephan Ruhrmann; Raimo K R Salokangas; Frauke Schultze-Lutter; Carolina Bonivento; Dominic Dwyer; Adele Ferro; Theresa Haidl; Marlene Rosen; Andre Schmidt; Eva Meisenzahl; Nikolaos Koutsouleris; Rachel Upthegrove Journal: Schizophr Bull Date: 2021-07-08 Impact factor: 9.306
Authors: Patrick Buosi; Fábio Aparecido Borghi; Angélica Marta Lopes; Isabela da Silva Facincani; Rafael Fernandes-Ferreira; Camila Ive Ferreira Oliveira-Brancati; Tayanne Silva do Carmo; Dorotéia Rossi Silva Souza; Danilo Grünig Humberto da Silva; Eduardo Alves de Almeida; Gerardo Maria de Araújo Filho Journal: Trends Psychiatry Psychother Date: 2021-01-01
Authors: Ivan Ristić; Stefan Jerotić; Mirjana Zebić; Bojana Savić; Vuk Vuković; Manuela Russo; Tatjana Voskresenski; Nikolina Jovanović; Nađa P Marić Journal: Front Psychol Date: 2020-10-26
Authors: Prasad R Padala; Kalpana P Padala; Anusha S Majagi; Kimberly K Garner; Richard A Dennis; Dennis H Sullivan Journal: Medicine (Baltimore) Date: 2020-08-14 Impact factor: 1.817